How I treat infant leukemia

Patrick Brown, Rob Pieters, Andrea Biondi

Research output: Contribution to journalArticle

Abstract

Leukemia in infants is rare but generates tremendous interest due to its aggressive clinical presentation in a uniquely vulnerable host, its poor response to current therapies, and its fascinating biology. Increasingly, these biological insights are pointing the way toward novel therapeutic approaches. Using representative clinical case presentations, we review the key clinical, pathologic, and epidemiologic features of infant leukemia, including the high frequency of KMT2A gene rearrangements. We describe the current approach to risk-stratified treatment of infant leukemia in the major international cooperative groups. We highlight recent discoveries that elucidate the molecular biology of infant leukemia and suggest novel targeted therapeutic strategies, including modulation of aberrant epigenetic programs, inhibition of signaling pathways, and immunotherapeutics. Finally, we underscore the need for increased global

collaboration to translate these discoveries into improved outcomes.

Original languageEnglish (US)
Pages (from-to)205-214
Number of pages10
JournalBlood
Volume133
Issue number3
DOIs
StatePublished - Jan 17 2019

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Brown, P., Pieters, R., & Biondi, A. (2019). How I treat infant leukemia. Blood, 133(3), 205-214. https://doi.org/10.1182/blood-2018-04-785980